Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jun 08 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Esomeprazole Magnesium for Delayed-Release Oral Suspension in two dosages. This medication is used to treat stomach and esophagus problems by reducing stomach acid production. The product will be manufactured at Zydus's facility in Moraiya, Ahmedabad. The press release highlights that the product had significant annual sales in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 08, 2023, titled "Zydus receives final approval from the USFDA for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases